Additional Research Studies Being Conducted by the ITN
Autoimmune Disease Clinical Trials
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis (BRAVOS)
BRAVOS is a clinical trial evaluating Brentuximab Vendotin treatment for Diffuse Cutaneous Systemic Sclerosis.
Allergy Clinical Trials
Vaginal Microbiome Exposure and Immune Responses in C-section Infants (ACTIVATE)
ACTIVATE is a clinical trial investigating the impact of the infant microbiome on allergy development.
Follow up of LEAP Participants and Their Families (LEAP Trio)
LEAP Trio is a follow-up to the LEAP study of early peanut consumption. LEAP Trio will investigate the durability of tolerance to peanut allergen in LEAP participants at age 12, development of peanut allergy in younger siblings of LEAP participants, and parental characteristics that may impact development of food allergy.
Transplantation Clinical Trials
Tolerance by Engaging Antigen During Cellular Homeostasis (TEACH)
TEACH is a clinical trial investigating whether cells from the kidney donor’s bone marrow, called mesenchymal stromal cells (MSCs) will allow kidney transplant recipients to stop immunosuppressive medications.
Liver Transplantation with Tregs at MGH and UCSF (LITTMUS)
LITTMUS is a clinical research study testing a new approach to achieve transplant tolerance using the liver transplant recipient’s own T regulatory cells (Tregs).
Allograft Tolerance Study (ALLTOL)
ALLTOL is an observational clinical study to learn more about tolerance in organ transplantation.
Type 1 Diabetes Clinical Trials
EXTEND Preserving Beta-Cell Function with Tocilizumab in New-Onset Type 1 Diabetes
The EXTEND study is a clinical research study testing whether tocilizumab (Actemra ®) can protect remaining beta cells in individuals recently diagnosed with type 1 diabetes and extend the ability to naturally produce insulin.
T1DES is a clinical study for people with type 1 diabetes who were previously enrolled in an ITN clinical study.
For more information about the ITN and other clinical trials, please visit immunetolerance.org.